-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
December 2017
-
Erlotinib, Crizotinib, Nivolumab: Big Three in ALCHEMIST Platform
By Caicun Zhou, MD, and Fei Zhou, MD Posted: December 2017 Adjuvant chemotherapy is the standard of care for patients with resected, early-stage non–small cell lung cancer (NSCLC), including stage II, IIIA, and larger (≥4cm) IB tumors. The survival improvement observed with adjuvant chemotherapy is moderate, with a 5-year 5% absolute benefit. In an effort…
-
Writing for Publication: Expanding the Voices of Nursing in Thoracic Oncology
By Kathleen A. Gamblin, RN, BSN, OCN Posted: December 2017 The nursing perspective and the views of other ancillary specialties are frequently missing in the thoracic oncology literature. This deficiency needs to be addressed; the current model of healthcare delivery in the US and around the world includes an ever-expanding role for nurses, nurse practitioners,…
-
The Lung Cancer Research Foundation and Free to Breathe Merge to Fight Lung Cancer
Posted: December 2017 Effective September 30, 2017, the Lung Cancer Research Foundation and Free to Breathe have merged organizations, with the goal of closing the funding gap for lung cancer research. The mission to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer continues in the newly…
-
Breaking News Briefs
• Alectinib (Alecensa) received full FDA approval for the first-line treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) as determined by an FDA-approved test. The approval was based on results from the phase III ALEX study that compared alectinib to crizotinib. In addition, the FDA also converted alectinib’s initial accelerated approval in…
-
Yasushi Yatabe, MD, PhD
Posted: December 2017 Yasushi Yatabe, MD, PhD, is the recipient of the 2017 IASLC Mary J. Matthews Pathology/Translational Research Award. Dr. Yatabe has served as Chief of the Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan, since 2000. Dr. Yatabe is Co-Editor of the IASLC Atlas of ALK and ROS1 Testing…
-
Ramon Rami-Porta, MD, PhD
Posted: December 2017 Ramón Rami-Porta, MD, PhD, is the recipient of the 2017 IASLC Merit Award. Dr. Rami-Porta was appointed this year as the Clinical Chief of the Department of Thoracic Surgery at Hospital Universitari Mútua Terrassa, in Terrassa (Barcelona), Spain. He is also a Collaborating Professor of Thoracic Surgery at Escola Universitária Gimbernat, Autonomous…
-
Carolyn M. Dresler, MD, MPA
Posted: December 2017 Carolyn M. Dresler, MD, MPA, is the recipient of the 2017 IASLC Joseph W. Cullen Prevention/Early Detection Award. Dr. Dresler is currently the Associate Director for Medical & Health Sciences, Center for Tobacco Products, US Food & Drug Administration (FDA), a position she has held since 2012. As an IASLC Board member…
-
Tony Mok, BMSc, MD, FRCP(C), FRCP (Glasgow), FASCO
Posted: December 2017 Tony Mok, BMSc, MD, FRCP(C), FRCP (Glasgow), FASCO, is the recipient of the 2017 IASLC Paul A. Bunn, Jr. Scientific Award. Prof. Mok is currently the Li Shu Fan Medical Foundation-Endowed Professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital. He also holds an honorary professorship at…
-
Lung Cancer Awareness Month Gathers Support and Momentum in Its Second Year
By Keightley Amen, BA, ELS Posted: December 2017 While many people remain unaware of the advancements in the field of lung cancer and research spending still lags behind the funds spent to combat other types of cancer,2 lung cancer is the leading cause of cancer death worldwide.1 To bolster research spending, raise public awareness, and…
-
Advocating for Inclusion of the Patient’s Voice
By Lori L. Alexander, MTPW, ELS, MWC Posted: December 2017 Since 2006, the Bonnie J. Addario Lung Cancer Foundation (ALCF) has brought together a diverse group of physicians, organizations, industry partners, and individuals, along with patients, survivors, and their families, to identify solutions and to make timely and meaningful changes in the research and management…